ReviewFrontiers in microbiology2020
Mumps Vaccines: Current Challenges and Future Prospects.
Review in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Mumps resurgence despite MMR: Limitations of current vaccines and the need for new strategies.Human vaccines & immunotherapeutics · 2026Review
- Serological Mumps Evaluation of Medical Students in Catalonia (Spain): Is a Third Dose of Vaccine Needed?Journal of medical virology · 2026Article
- Mumps Virus: Replication, Immune Response, and the Changing Landscape of Vaccine Effectiveness.Pathogens (Basel, Switzerland) · 2026Review
- A phase 1, single-center, randomized, dose finding study to evaluate the safety, tolerability, and immunogenicity of a prophylactic COVID-19 pDNA vaccine after single ascending doses in healthy adults.Frontiers in medicine · 2026Article
- Article
- The effect of mumps vaccine on the incidence of mumps in Hefei: An interrupted time-series analysis.Human vaccines & immunotherapeutics · 2025Article
- Evaluation and optimization of mumps-containing vaccination strategies: a study based on an individual-based stochastic model.EClinicalMedicine · 2025Article
- Incremental effectiveness of the second dose of mumps-containing vaccine among children 9 months to 6 years in Hefei: A matched case-control study.Human vaccines & immunotherapeutics · 2025Article
- Challenging 21-day quarantine guidelines for mumps in Beijing: Data-driven recommendations for a high-coverage MMR vaccination era (2019-2024).Human vaccines & immunotherapeutics · 2025Article
- Review
- Collective Immunity to the Measles, Mumps, and Rubella Viruses in the Kyrgyz Population.Vaccines · 2025Article
- Development and characterization of the genotype F attenuated mumps candidate strains.Frontiers in immunology · 2025Article
- Spatial stratified heterogeneity of mumps incidence in China: a Geodetector-based analysis of driving factors.Frontiers in public health · 2025Article
- Glycosylation as a strategic mechanism for measles virus and mumps virus immune evasion.Frontiers in immunology · 2025Review
- An Investigation of MMR-Related Mumps Cluster Following Immunization Among Practical Nursing Students, Bangkok, Thailand, 2024.Journal of tropical medicine · 2025Article
- Article
- Exploration of microRNAs as transcriptional regulator in mumps virus infection through computational studies.Scientific reports · 2024Article
- Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective.Nature communications · 2024Article
- Epidemiologic and clinical updates on viral infections in Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Immunogenicity and Cross-Protection Efficacy of a Genotype F-Derived Attenuated Virus Vaccine Candidate against Mumps Virus in Mice.Vaccines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Five decades have passed since the first mumps vaccine was licensed. Over this period, a resurgence of mumps infections has been recorded worldwide. Although global mumps infections have been controlled through vaccination, outbreaks are still on the rise, including in populations with high vaccination coverage. Several epidemiological studies suggest that this infectious virus continues to be a worldwide public health threat. The development and deployment of an improved, prophylactic mumps vaccine that provides long-lasting protection is indeed a priority. The purpose of this review is to provide an immuno-biological perspective on mumps vaccines. Here, we review the virology of mumps, licensed mumps vaccines, and the typical immune responses elicited following mumps vaccination. Furthermore, we discuss the limitations and challenges of the currently licensed mumps vaccines and provide strategies for the development of an improved mumps vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.